Last reviewed · How we verify
Phenylbutazon (PHENYLBUTAZONE)
Phenylbutazone is a small molecule drug developed by SANDOZ, targeting nicotinate phosphoribosyltransferase. It is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylbutazone class, approved by the FDA in 1980 for various indications. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its potential for bone marrow suppression and gastrointestinal toxicity. Phenylbutazone is a commercial product with a high bioavailability of 90%.
At a glance
| Generic name | PHENYLBUTAZONE |
|---|---|
| Sponsor | Novartis |
| Drug class | phenylbutazone |
| Target | Nicotinate phosphoribosyltransferase, Prostacyclin synthase, Cytochrome P450 2C9 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1980 |
Approved indications
Common side effects
Drug interactions
- warfarin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenylbutazon CI brief — competitive landscape report
- Phenylbutazon updates RSS · CI watch RSS
- Novartis portfolio CI